Merck Animal Health has agreed to acquire TARGAN, a technology company serving the poultry industry, according to an announcement reported by The Poultry Site.

The deal transfers TARGAN and its product line into one of the largest animal health companies in the world. Merck Animal Health, the veterinary division of Merck & Co., already holds a broad portfolio spanning pharmaceuticals, vaccines and parasite control products across companion-animal and livestock species, including a substantial poultry business.

For poultry producers and the veterinarians who advise them, the acquisition signals continued consolidation of precision-livestock technology into the hands of major pharmaceutical manufacturers. Integrating a technology platform with an established commercial and regulatory infrastructure typically accelerates the route from innovation to widespread adoption in integrated poultry operations.

Neither company disclosed the financial terms of the transaction in the announcement. Additional details regarding the closing timeline, regulatory review requirements and how TARGAN's products will be integrated into the Merck Animal Health portfolio were not specified.

TARGAN has positioned itself as a developer of advanced technologies for the poultry sector, an industry under sustained pressure to improve bird-level monitoring, welfare outcomes and production efficiency at scale.

The acquisition fits a broader industry pattern. Major animal health manufacturers have moved to add data-driven and automated systems to their traditional drug and vaccine offerings, reflecting demand from integrated poultry producers for tools that deliver bird-level insight alongside health interventions.

For food-animal practitioners, the practical question following the deal will be how Merck Animal Health distributes, supports and potentially expands TARGAN's technology across global poultry markets. Companion-animal and public-health implications appear limited, as the transaction centers on poultry production technology rather than pharmaceutical products with cross-species use.

Industry observers will watch for confirmation of the transaction's completion and any statements on product roadmaps once the acquisition closes.